Biohaven Enters Into Agreement With Genpharm For Distribution Of NURTEC ODT In The Middle East

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) and Genpharm Services, a leading partner for innovative pharmaceuticals in Dubai, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in the Middle East and Gulf countries. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

Donnie McGrath, Head of Corporate Strategy and Business Development of Biohaven commented, “Our agreement with Genpharm is further evidence of our commitment to make NURTEC ODT as widely available as possible to patients suffering from migraine, and as quickly as possible, regardless of location. We are excited to partner with the team at Genpharm to bring what we believe is the best-in-class oral small molecule CGRP-antagonist NURTEC ODT to migraine patients in the Middle East region”.

Karim Smaira and Kamel Ghammachi, Co-Founders of Genpharm Services commented, “Migraine represents a significant and underappreciated burden for both patients and society in the Middle East, and our mission is to bring innovative medicines that can address unmet needs in this region. We are proud to work with Biohaven Pharmaceuticals to bring the benefits of the new CGRP-antagonist NURTEC ODT for the acute treatment of migraine to patients in the region.”

Dr. Mohammed Al Jumah, Professor of Neurology, Saudi Arabia commented, “Migraine is very common in the Middle East, possibly more common than in other parts of the world. Practices across the region see many patients who fear every day that their life will be disrupted by a migraine attack. Many are unsure if their current treatment will work and if they can manage the many side effects of their current treatments. Fortunately, there has been innovation in migraine treatments recently, and now patients have the option of NURTEC ODT, a new oral tablet that is effective, well tolerated and easy to use for the acute treatment of migraine. It brings hope for people living with migraine that they can quickly treat their migraine and get back to living their lives without fear of the next attack.”

The agreement between Biohaven and Genpharm includes NURTEC ODT, approved in the USA on February 27, 2020 for the acute treatment of migraine.-PR Newswire